Clinical data from ongoing Phase I dose escalation and expansion study of monalizumab and Imfinzi® (durvalumab) in colorectal cancer patients presented at 2018 ASCO annual meeting
Preliminary data from a Phase I dose escalation and expansion study of monalizumab and Imfinzi® (durvalumab) show anti-tumor activity in colorectal cancer patients
First quarter 2018 report
Preliminary data suggest promising anti-tumor activity of the combination of monalizumab and cetuximab in patients with platinum pretreated SCCHN
New preclinical data further support ongoing programs and highlight next generation of immunotherapies
Partner MedImmune expands colorectal cancer patient cohort in ongoing Phase I trial evaluating monalizumab in combination with Imfinzi® (durvalumab)
Innate Pharma to present broad and innovative portfolio in immuno-oncology at AACR 2018
Innate Pharma Hosts R&D Day Today in London
Innate Pharma provides an update on Lirilumab
First half of 2017: delivering key clinical data and strengthening the pipeline
